ImmunoPrecise Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ImmunoPrecise Antibodies
HYFT Stock   1.39  0.02  1.46%   
Analyzing historical trends in various income statement and balance sheet accounts from ImmunoPrecise Antibodies' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ImmunoPrecise Antibodies' valuation are summarized below:
Gross Profit
14.1 M
Profit Margin
(1.16)
Market Capitalization
81.7 M
Enterprise Value Revenue
3.3574
Revenue
25.2 M
There are currently one hundred twenty fundamental trends for ImmunoPrecise Antibodies that can be evaluated and compared over time across competitors. All traders should confirm ImmunoPrecise Antibodies' regular fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 2.7 M in 2026. Enterprise Value is likely to drop to about 2.7 M in 2026

ImmunoPrecise Antibodies Total Revenue

29.35 Million

Check ImmunoPrecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunoPrecise Antibodies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.1 M, Total Revenue of 29.4 M or Gross Profit of 13.9 M, as well as many indicators such as Price To Sales Ratio of 1.7 K, Dividend Yield of 0.0863 or Days Sales Outstanding of 3.3 K. ImmunoPrecise financial statements analysis is a perfect complement when working with ImmunoPrecise Antibodies Valuation or Volatility modules.
  
Build AI portfolio with ImmunoPrecise Stock
Check out the analysis of ImmunoPrecise Antibodies Correlation against competitors.
For more information on how to buy ImmunoPrecise Stock please use our How to Invest in ImmunoPrecise Antibodies guide.

ImmunoPrecise Antibodies Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets53.7 M51.1 M31.6 M
Slightly volatile
Total Current Liabilities10.9 M10.4 M4.8 M
Slightly volatile
Property Plant And Equipment Net19.6 M18.7 M5.8 M
Slightly volatile
Accounts Payable6.4 M6.1 M2.1 M
Slightly volatile
Cash12.9 M12.3 M7.8 M
Slightly volatile
Non Current Assets Total31 M29.5 M19.4 M
Slightly volatile
Cash And Short Term Investments12.9 M12.3 M7.9 M
Slightly volatile
Net Receivables5.8 M5.5 M2.3 M
Slightly volatile
Common Stock Shares Outstanding40.3 M38.4 M14.3 M
Slightly volatile
Short Term Investments88.9293.6154.9 K
Slightly volatile
Liabilities And Stockholders Equity53.7 M51.1 M31.6 M
Slightly volatile
Other Current Assets1.4 M1.4 M872.3 K
Slightly volatile
Other Stockholder Equity9.4 M11.5 M9.9 M
Pretty Stable
Total Liabilities25.1 M23.9 M10.7 M
Slightly volatile
Total Current Assets22.6 M21.6 M12.2 M
Slightly volatile
Non Current Liabilities Total7.2 M13.6 M5.9 M
Slightly volatile
Short and Long Term Debt Total16.2 M15.4 M5.4 M
Slightly volatile
Short Term Debt3.9 M3.7 M1.5 M
Slightly volatile
Inventory1.3 M2.4 M953.8 K
Slightly volatile
Intangible Assets1.2 M1.2 M7.4 M
Slightly volatile
Common Stock164.7 M156.8 M57.9 M
Slightly volatile
Good Will11.5 M9.5 M8.2 M
Slightly volatile
Capital Lease Obligations9.8 M15.4 M4.5 M
Slightly volatile
Net Invested Capital38.7 M21.3 M64.5 M
Slightly volatile
Property Plant And Equipment Gross19.8 M27.6 M13.2 M
Slightly volatile
Short and Long Term Debt1 M1.2 M1.3 M
Slightly volatile
Capital Stock134.2 M156.8 M120 M
Slightly volatile
Net Working Capital10.4 M8.8 M22.4 M
Slightly volatile

ImmunoPrecise Antibodies Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization6.1 M5.8 M2.5 M
Slightly volatile
Total Revenue29.4 M28 M12.3 M
Slightly volatile
Other Operating Expenses44.2 M42.1 M19 M
Slightly volatile
Total Operating Expenses28.7 M27.3 M11.5 M
Slightly volatile
Interest Expense10.8 K11.4 K145 K
Pretty Stable
Cost Of Revenue15.5 M14.7 M7.5 M
Slightly volatile
Selling General Administrative17.8 M16.9 M7.8 M
Slightly volatile
Selling And Marketing Expenses5.2 M4.9 M1.6 M
Slightly volatile
Research Development3.4 M5.6 M2.7 M
Slightly volatile
Interest Income19.7 K20.7 K209.2 K
Slightly volatile
Reconciled Depreciation5.9 M5.9 M4.4 M
Slightly volatile

ImmunoPrecise Antibodies Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow4 M4.1 M6.3 M
Slightly volatile
Depreciation6.2 M5.9 M2.5 M
Slightly volatile
End Period Cash Flow13 M12.4 M7.8 M
Slightly volatile
Stock Based Compensation486.2 K511.8 K889.9 K
Slightly volatile
Dividends Paid94.7 K81 K120.6 K
Slightly volatile
Issuance Of Capital Stock14.8 M14.1 M5.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.7 K3.2 K295
Slightly volatile
Dividend Yield0.08630.08220.0497
Slightly volatile
Days Sales Outstanding3.3 K3.5 K462
Slightly volatile
Average Payables245.1 K130.6 K318.7 K
Slightly volatile
Stock Based Compensation To Revenue0.020.02110.0826
Pretty Stable
Capex To Depreciation18.5619.53464.2991
Slightly volatile
EV To Sales3.3 K3.2 K386
Slightly volatile
Inventory Turnover0.520.54926.4699
Very volatile
Days Of Inventory On Hand698665540
Slightly volatile
Payables Turnover0.00550.00582.6606
Slightly volatile
Sales General And Administrative To Revenue0.750.70.6983
Pretty Stable
Average Inventory5.8 K6.1 K261.2 K
Very volatile
Research And Ddevelopement To Revenue0.170.180.2198
Very volatile
Capex To Revenue21.8623.01552.7473
Slightly volatile
Cash Per Share0.06930.07290.4397
Pretty Stable
Days Payables Outstanding66.5 K63.3 K24.7 K
Pretty Stable
Intangibles To Total Assets0.02710.02850.3499
Pretty Stable
Current Ratio0.160.16951.9795
Very volatile
Receivables Turnover0.09980.1054.726
Slightly volatile
Capex Per Share0.03510.03690.0413
Slightly volatile
Average Receivables1.3 K1.4 K781.7 K
Slightly volatile
Revenue Per Share0.00210.00220.7071
Pretty Stable
Interest Debt Per Share0.150.13510.2024
Slightly volatile
Debt To Assets1.681.60360.5001
Pretty Stable
Operating Cycle631665577
Slightly volatile
Days Of Payables Outstanding66.5 K63.3 K24.7 K
Pretty Stable
Long Term Debt To Capitalization0.310.30.1839
Very volatile
Quick Ratio0.160.16951.8739
Very volatile
Net Income Per E B T0.740.71570.9609
Slightly volatile
Cash Ratio0.01440.01511.1646
Pretty Stable
Days Of Inventory Outstanding698665540
Slightly volatile
Days Of Sales Outstanding3.3 K3.5 K462
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.481.56271.3445
Slightly volatile
Fixed Asset Turnover5.0E-46.0E-43.48
Slightly volatile
Debt Ratio1.681.60360.5001
Pretty Stable
Price Sales Ratio1.7 K3.2 K295
Slightly volatile
Asset Turnover4.0E-44.0E-40.454
Slightly volatile

ImmunoPrecise Antibodies Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.7 M2.8 M41 M
Slightly volatile
Enterprise Value2.7 M2.9 M37.8 M
Slightly volatile

ImmunoPrecise Fundamental Market Drivers

About ImmunoPrecise Antibodies Financial Statements

ImmunoPrecise Antibodies shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ImmunoPrecise Antibodies investors may analyze each financial statement separately, they are all interrelated. The changes in ImmunoPrecise Antibodies' assets and liabilities, for example, are also reflected in the revenues and expenses on on ImmunoPrecise Antibodies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.3 M
Total Revenue28 M29.4 M
Cost Of Revenue14.7 M15.5 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.70  0.75 
Research And Ddevelopement To Revenue 0.18  0.17 
Capex To Revenue 23.02  21.86 
Ebit Per Revenue(603.21)(633.37)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ImmunoPrecise Stock Analysis

When running ImmunoPrecise Antibodies' price analysis, check to measure ImmunoPrecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunoPrecise Antibodies is operating at the current time. Most of ImmunoPrecise Antibodies' value examination focuses on studying past and present price action to predict the probability of ImmunoPrecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunoPrecise Antibodies' price. Additionally, you may evaluate how the addition of ImmunoPrecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY